Author(s)

Xueling Fang^1*, Fang Lin^2*, Qianqian Lei³, Xuegang Li^1#

¹Department of Rheumatology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
²Department of Infectious Disease, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
³Department of Pneumology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.

Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease which is characterized by the involvement of the sacroiliac joint and the spine, the main therapy includes biological agents, which may increase the risk of tumor and infection in long term application. Case Presentation: A fifty-year- old man was diagnosed of AS. He received the therapy of golimumab 50 mg once every one month subcutaneously. After receiving this treatment for two years and eight months, the patient had an elevated level of IgA. The monoclonal protein was finally identified as the type of IgA-kappa from the immunofixation study. Bone marrow aspirate smear revealed infiltration by plasma cells (5%) and immunophenotyping was positive for CD27, CD28, CD38, CD45, CD138 and cKappa, which was finally diagnosed of MGUS. Conclusion: This case demonstrates that golimumab may increase the risk of premalignant disease in patients with AS. With our case report, we also like to highlight that patients with AS may have increased risk of plasma cell malignancies.

Ankylosing Spondylitis, Golimumab, Monoclonal Gammopathy of Undetermined Significance

Fang, X. , Lin, F. , Lei, Q. and Li, X. (2022) Monoclonal Gammopathy of Undetermined Significance Occurred after Golimumab Therapy in a Patient with Ankylosing Spondylitis. Case Reports in Clinical Medicine, 11, 494-498. doi: 10.4236/crcm.2022.1112067.